^
Association details:
Biomarker:BAP1 mutation
Cancer:Mesothelioma
Drug:Tazverik (tazemetostat) (EZH2 inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
Go to data
Title:

Study of the EZH2 Inhibitor Tazemetostat in Malignant Mesothelioma

Excerpt:
...Part 2: Molecular evidence of BAP1 loss of function mutation present on local pathology, e.g., lack of nuclear BAP1 staining by immunohistochemistry (IHC) or evidence of loss of function by gene sequencing 7....
Trial ID:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

Safety and efficacy of tazemetostat, an enhancer of zeste-homolog 2 inhibitor, in patients with relapsed or refractory malignant mesothelioma.

Published date:
05/13/2020
Excerpt:
The study enrolled 74 pts with R/R malignant mesothelioma, 70 pts (95%) were centrally confirmed to be BAP1-deficient....Based on disease control rate and stable disease, TAZ showed antitumor activity in pts with BAP1-deficient R/R malignant mesothelioma.
DOI:
10.1200/JCO.2020.38.15_suppl.9058
Trial ID: